Am­gen, As­traZeneca speed to­ward fil­ing next-gen an­ti­body for asth­ma af­ter un­cork­ing full late-stage da­ta

On the hunt for a nov­el com­peti­tor to Sanofi and Re­gen­eron’s Dupix­ent in se­vere asth­ma, Am­gen and As­traZeneca post­ed “ex­cit­ing” re­sults from their next …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.